naptumomab estafenatox
Showing 1 - 5 of 5
Urothelial Carcinoma Trial in New York (Naptumomab Estafenatox, Pembrolizumab, Obinutuzumab)
Not yet recruiting
- Urothelial Carcinoma
- Naptumomab Estafenatox
- +2 more
-
New York, New YorkWeill Cornell Medicine/NewYork-Presbyterian Hospital
May 30, 2023
NSCLC Trial in United States (NAP (Naptumomab estafenatox), Docetaxel, Obinutuzumab)
Recruiting
- Non-small Cell Lung Cancer
- NAP (Naptumomab estafenatox)
- +2 more
-
Daphne, Alabama
- +9 more
Oct 20, 2021
Renal Cell Carcinoma Trial in Worldwide (ABR-217620/naptumomab estafenatox, IFN-alpha)
Completed
- Renal Cell Carcinoma
- ABR-217620/naptumomab estafenatox
- IFN-alpha
-
Pleven, Bulgaria
- +50 more
Jun 30, 2015
NSCLC Trial in Philadelphia, Copenhagen, St. Petersburg (ABR-217620, docetaxel)
Completed
- Carcinoma, Non-Small-Cell Lung
-
Philadelphia, Pennsylvania
- +3 more
Aug 26, 2014
Non-Small-Cell Lung Carcinoma, Renal Cell Carcinoma, Pancreatic Cancer Trial in Philadelphia, Oslo, Manchester (ABR-217620)
Completed
- Non-Small-Cell Lung Carcinoma
- +2 more
-
Philadelphia, Pennsylvania
- +2 more
Aug 26, 2014